LAVA Therapeutics NV (LVTX) - Cash Flow Conversion Efficiency
Based on the latest financial reports, LAVA Therapeutics NV (LVTX) has a cash flow conversion efficiency ratio of -0.384x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.87 Million) by net assets ($12.68 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See LVTX net asset quality score to measure how much of total assets are equity-financed.
LAVA Therapeutics NV - Cash Flow Conversion Efficiency Trend (2019–2024)
This chart illustrates how LAVA Therapeutics NV's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check LAVA Therapeutics NV (LVTX) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
LAVA Therapeutics NV Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of LAVA Therapeutics NV ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mercal Inmuebles Socimi SA
MC:YMEI
|
-0.002x |
|
Banswara Syntex Limited
NSE:BANSWRAS
|
0.035x |
|
LGL Group Inc
NYSE MKT:LGL
|
0.011x |
|
Ege Seramik Sanayi ve Ticaret AS
IS:EGSER
|
-0.103x |
|
Mendus AB (publ)
ST:IMMU
|
-0.037x |
|
Golden House
TA:GOHO
|
0.019x |
|
Dedicare AB (publ)
ST:DEDI
|
-0.118x |
|
Ji-Haw Industrial Co Ltd
TW:3011
|
-0.055x |
Annual Cash Flow Conversion Efficiency for LAVA Therapeutics NV (2019–2024)
The table below shows the annual cash flow conversion efficiency of LAVA Therapeutics NV from 2019 to 2024. For the full company profile with market capitalisation and key ratios, see LAVA Therapeutics NV (LVTX) total market value.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $27.75 Million | $-19.54 Million | -0.704x | +10.51% |
| 2023-12-31 | $51.18 Million | $-40.28 Million | -0.787x | -1775.08% |
| 2022-12-31 | $86.04 Million | $4.04 Million | 0.047x | +119.42% |
| 2021-12-31 | $118.37 Million | $-28.65 Million | -0.242x | +80.18% |
| 2020-12-31 | $7.62 Million | $-9.31 Million | -1.221x | +17.16% |
| 2019-12-31 | $5.84 Million | $-8.62 Million | -1.474x | -- |
About LAVA Therapeutics NV
LAVA Therapeutics N.V. operates as a clinical-stage immuno-oncology company that focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage can… Read more